January 14, 2021
Jan 14, 2021
Medical Director | DVC Stem
A new press release by Vitro Biopharma a CLIA, ISO9001, ISO13485 certified laboratory in Golden, Colorado, USA, has announced a remarkable COVID-19 patient recovery after being treated with expanded cord tissue-derived mesenchymal stem cells.
The current global state of COVID-19 is looming over many. Daily news reports, Facebook posts & blog articles express a gloomy future outlook that can cause anxiety and stress among many.
However, encouraging news and data does sometimes find its way into the public sphere. Mesenchymal stem cells are beginning to show promise as a potential treatment for COVID-19.
A new press release by Vitro Diagnostics, Inc, dba Vitro Biopharma a CLIA, ISO9001, ISO13485 certified laboratory in Golden, Colorado, USA, has announced a remarkable COVID-19 patient recovery after being treated with expanded cord tissue-derived mesenchymal stem cells.
The patient initially admitted into an emergency room with traditional COVID-19 symptoms. The patient had several comorbidities (more than one pre-existing medical condition) before hospital admission. Doctors initially used a standard treatment (yet still experimental) with convalescent plasma, but the patient's condition continued to worsen. While in the intensive care unit (ICU), the patient's liver and kidney functions began to fail. The patient also experienced sepsis and a stroke, cumulatively placing the patient in a coma for almost seven weeks.
The FDA authorized a study through an Investigational Drug Application (eIND) for emergency use of Vitro Biopharma's AlloRx Stem Cells® (cord tissue-derived mesenchymal stem cells) as a therapeutic agent.
Following the treatment with Vitro Biopharma's culturally expanded cord tissue-derived mesenchymal stem cells, the patient experienced resolution of multiple organ function failure, recovery from coma and restoration of neurological, pulmonary, liver, and renal function. (1) Resulting in the patient being removed from dialysis and assissted respiration machines.
The patient has not only gained the ability to eat, drink, and speak but has also regained motor function. The patient's inflammation levels have also dropped back down to normal. The patient has now been discharged from the intensive care unit and follows a physical therapy regime to improve mobility.
According to Dr. Jack Zamora, MD, Vitro Biopharma's Chief Medical Advisor:
"The miraculous recovery of our first critically ill COVID-19 patient using AlloRx Stem Cells brings great hope in these troubling times."
This recovery shows the exciting promise of mesenchymal stem cells' ability to treat inflammation and help resolve issues such as organ failure. The natural immunomodulatory capabilities of Mesenchymal Stem Cells may be among the most effective ways to reduce inflammatory cytokine damage in the lungs caused by COVID-19.
Dr. Jim Musick, CEO of Vitro Biopharma, states:
"We are pleased to have achieved this milestone based on a thorough understanding of the science of stem cell biology. While regeneration of destroyed cells is a common effect of stem cell therapy, stem cells also regenerate damaged cells by various regenerative processes that restore normal organ function. This case supports the further study of AlloRx Stem Cell® Therapy for COVID-19 patients and other conditions characterized by acute respiratory distress that are ultimately related to the inflammatory cytokine cascade neutralized by the cord tissue-derived mesenchymal stem cells. "
DVC Stem is partnered with Vitro Biopharma, an award-winning medical laboratory located in Golden, Colorado, fully FDA-registered, cGMP compliant, ISO 9001, and ISO 13485 certified. Cells are only sourced from the American Association of Tissue Bank (AATB) certified suppliers of full-term, ethically US donated human umbilical cords. The selection of these donated tissues is exceptionally regulated and strict. All of its cells are expanded using safe and standard protocols and are then flown overnight in sub-zero containers directly to our clinic for immediate treatment. The cells are expanded to as many as 300 million cells before being administered. For more info on its partner lab, visit www.vitrobiopharma.com.
(1) Critically Ill COVID-19 Patient Successfully Treated with Vitro Biopharma's AlloRx Stem Cells®. 15 July 2020, vitrobiopharma.com/critically-ill-covid-19-patient-successfully-treated-with-vitro-biopharmas-allorx-stem-cells/.
About the author
Dr. Cona has been performing stem cell therapy for over 10 years. He is a member of the World Academy of Anti-Aging Medicine (WAAAM). He is also a recognized member of the British Medical Association, the General Medical Council (UK), the Caribbean College of Family Physicians, and the American Academy of Family Physicians. He is the Medical Director for DVC Stem a world-renowned stem cell therapy clinic located in Grand Cayman.
Are you a candidate for stem cell treatment?
Complete our brief online application to find out if our IRB-approved mesenchymal stem cell treatment is right for you.Apply for treatment
You might also like...
The borders of the Cayman Islands are in a phased reopening process, which will expand within the next couple of months. This means that the airport is open but travel must be approved by the Cayman Islands Government & all visitors must participate in a mandatory 10 - 14 day quarantine.
Stem cell therapy results have been extremely positive so far, with approximately 75% of Multiple Sclerosis patients reporting significant improvement within 3 months of treatment, and showing little to no signs of regression out to 18-24 months. Our full Multiple Sclerosis study results are expected to be published later this year.
New study has found mesenchymal stem cells to be both a safe and effective treatment option for stroke.
Are people with Multiple Sclerosis more prone to severe Coronavirus related illness? Having a compromised immune system could potentially increase one’s risk of developing severe Coronavirus symptoms. This article aims to answer this question as well as describe the actions MS patients should take to mitigate risk.
Explaining the relationship between stem cell therapy and Parkinson's.
DVC STEM, GRAND CAYMAN